What You Ought to Know:
– Doximity, a digital platform for U.S. medical professionals, has acquired Pathway Medical Inc., a Montreal-based startup specializing in medical AI and evidence-based scientific reference.
– The acquisition, valued at $26M in money with as much as a further $37M in fairness grants, closed on July 29, 2025. The strategic transfer is about to considerably improve Doximity’s scientific reference capabilities by integrating Pathway’s superior AI platform and intensive medical dataset.
A Information-Pushed Method to Scientific Accuracy
Pathway’s group, which is half-comprised of physicians, has spent seven years meticulously constructing one of many largest structured datasets in drugs. This dataset, purpose-built for AI, covers almost each medical guideline, drug, and landmark trial throughout all main specialties. This rigorous, evidence-based basis is a key motive for Pathway’s success; its AI mannequin not too long ago achieved a record-breaking 96% on the U.S. Medical Licensing Examination (USMLE) benchmark, outperforming different fashions in scientific accuracy.
The merger of Pathway and Doximity is poised to democratize entry to those cutting-edge scientific instruments. Pathway has already garnered a robust following, with a whole bunch of 1000’s of registered customers and 1000’s paying for its premium product. By integrating its know-how into Doximity’s platform, Pathway’s CEO, Jon Hershon, is worked up to “convey that have to thousands and thousands without spending a dime, constructed immediately into the instruments they already use on the level of care.”
Bringing AI-Powered Instruments to Tens of millions of Docs
The acquisition will tackle the rising want for scientific instruments that mix trusted, evidence-based data with the pace and flexibility of AI. With Doximity’s huge community, which incorporates over 80% of U.S. physicians, the combination of Pathway’s AI will empower an infinite person base with immediate, evidence-based solutions to medical questions, serving to docs be extra productive and supply higher care for his or her sufferers.
Jeff Tangney, co-founder and CEO of Doximity, expressed his enthusiasm for the acquisition, stating, “They’ve painstakingly constructed among the best datasets in drugs, and it’s going to take our scientific reference capabilities to a completely new degree.”
